New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 23, 2012
20:19 EDTZQK, PG, NLY, HPQ, OPEN, AZN, AGNC, CNX, CRM, WFT, THLD, GOOG, IBM, VVUSJim Cramer's "Mad Money"
Jim Cramer dedicated his first segment to the art of the calculated long-shot. He always preached diversification, staying in a mix of stocks to minimize their downside risk. But Cramer said that he also always preaches speculation, picking one stock with huge upside potential. One of those speculative picks paid off big Thursday was Vivus (VVUS) -- a fledgling drug maker that received approval for the first weight-loss drug to be approved in over 13 years. The shares soared over 78% Thursday. He said investors need to stay with the tried and true stocks, those like IBM (IBM) and Procter & Gamble (PG), both of which enjoyed small rallies Thursday, but having a speculative stock like Vivus makes investing all the more enjoyable. EXECUTIVE DECISION: Cramer spoke with Marc Benioff, CEO of Salesforce.com (CRM), a stock that came under fire when it last reported in November, but also one that was able to redeem itself Thursday with a 3c earnings beat on a 38% rise in revenues yoy. Cramer said Salesforce.com continues to deliver and he continued to recommend the stock. Then, Cramer sat down with Matt Roberts, president and CEO of OpenTable (OPEN), a momentum stock that fell out of favor in late-2011 but has since been crawling back to life, up 45% from its November lows. Roberts said he sees tremendous growth opportunities as only 12% of all restaurant reservations are currently being made online. He dispelled the notion that higher gas prices slow the company's growth. And said that Google (GOOG) is a partner, not a competitor. Cramer said that OpenTable's market cap is too small given the size of the opportunities the company has yet to address. He once again recommended owning the stock. SELL BLOCK: Consol Energy (CNX) has major headwinds. Cramer said with coal and natural gas both in the doghouse, Consol Energy should be there as well. NO HUDDLE OFFENSE: Cramer said the tech industry is filled with once great companies that have faltered and Hewlett-Packard (HPQ) may be next in line. The company has drained its resources, leaving it vulnerable. Previous management made a slew of terrible decisions, from stock buybacks at inflated prices to acquisitions that made no sense, Cramer said. New CEO, Meg Whitman, has a mixed track record of success, said Cramer, and her comments Thursday offered no real vision or cost-cutting initiatives. He advised investors to steer clear of Hewlett and invest in their rivals, as HP is now too big for a takeover, too complex to be broken up and too drained to advance under its own power. LIGHTNING ROUND: (Bullish) THLD; AGNC; NLY. (Bearish) WFT; AZN; ZQK. Reference Link
News For VVUS;IBM;PG;CRM;OPEN;GOOG;CNX;HPQ;THLD;AGNC;NLY;WFT;AZN;ZQK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
December 10, 2014
13:10 EDTCRMSalesforce.com management to meet with FBR Capital
Subscribe for More Information
10:53 EDTCRMSalesforce.com calls active on activist investor speculation
Subscribe for More Information
10:05 EDTCRMRumor: Salesforce.com moves up on activist investor speculation
08:36 EDTIBMApple, IBM deliver first wave of IBM MobileFirst for iOS apps
Apple (AAPL) and IBM (IBM) have delivered the first wave of IBM MobileFirst for iOS solutions in a new class of made-for-business apps and supporting cloud services that bring IBM’s big data and analytics capabilities to iPhone and iPad users in the enterprise. IBM MobileFirst for iOS solutions are now available to enterprise customers in banking, retail, insurance, financial services, telecommunications and for governments and airlines, thanks to an unprecedented collaboration between Apple and IBM. IBM clients today announcing support for IBM MobileFirst for iOS solutions include: Citi, Air Canada, Sprint and Banorte.
08:25 EDTHPQHP capital return potential makes valuation attractive, says Brean Capital
Subscribe for More Information
08:16 EDTIBMBarclays to hold a conference
Global Technology Conference is being held in San Francisco on December 9-10 with webcasted company presentations to begin on December 10 at 10:40 am; not all company presentations may be webcasted.Webcast Link
December 9, 2014
10:09 EDTCNXCONSOL management to meet with FBR Capital
Meeting to be held in Kansas City on December 11 hosted by FBR Capital.
09:10 EDTAZNARIAD takeover rumors rekindled, Independent says
Subscribe for More Information
08:02 EDTAZNMoventig approved in EU for opioid-induced constipation
Nektar (NKTR) reported partner AstraZeneca (AZN) announced that MOVENTIG has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative. MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist to be approved in the European Union.
07:44 EDTAZNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:14 EDTGOOGGoogle launches Street View in Dubai
Subscribe for More Information
06:00 EDTCRM, GOOGSalesforce.com names YouTube CEO Susan Wojcicki to board
Subscribe for More Information
December 8, 2014
10:42 EDTNLYOptions with increasing implied volatility
Subscribe for More Information
07:28 EDTCRM, HPQFBN Securities to hold a bus tour
Subscribe for More Information
07:05 EDTAZNInnocoll appoints Tony Zook as CEO
Innocoll AG (INNL) announced that Tony Zook, formerly executive vice president, Global Commercial Operations, at AstraZeneca (AZN), has been appointed CEO effectively immediately. Michael Myers, will continue with the company as head of Portfolio Operations.
06:59 EDTCNXCONSOL removed from short-term buy list at Deutsche Bank
Deutsche Bank removed CONSOL from the short-term buy list due to an automatic six month demotion.
December 7, 2014
16:48 EDTTHLDThreshold Pharmaceuticals announces data from TH-302 study
Threshold Pharmaceuticals announced new preliminary data from the Phase 2 component of an ongoing company-sponsored Phase 1/2 trial of TH-302, the company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib, Velcade, and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma. The median number of prior therapies was 8. The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses were observed in 2 of 7 evaluable patients overall and 2 of 4 evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California.
15:53 EDTHPQHP shares could gain 15%, Barron's says
HP shares could gain 15% to $45.00 per share as the company splits its enterprise business from PCs and printer business, by next October, Barron's argues in a follow up article. Reference Link
14:10 EDTTHLDAmerican Society of Hematology to hold a meeting
Subscribe for More Information
13:47 EDTGOOGGoogle could reach $634 in a year, Barron's says
Google shares look attractive at current levels and shares could reach $634.00 in a year, driven by stabilizing ad pricing, Barron's contends in a feature article. Reference Link
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use